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ORIGINAL ARTICLE
Introduction: We aim to develop a simple and sensitive array-based 
method for the detection of epidermal growth factor receptor (EGFR) 
gene mutations in the plasma of non–small-cell lung cancer patients 
and determine its use in the follow-up of those on tyrosine-kinase 
inhibitor (TKI) therapy.
Method: DNA from 100 μl of plasma was amplified in the presence 
of peptide nucleic acid clamp to provide single-stranded template 
for the allele-specific arrayed primer extension reaction, incorporat-
ing cyanine-5-deoxycytidine triphosphate in the newly synthesized 
strands. The fluorescent product was visualized by laser at 670 nm.
Results: Eleven different types of EGFR TKI drug-sensitive mutants 
(SM) were identified in plasma-DNA from 46 of 51 patients. Five 
patients carried only wild-type sequence. Plasma-DNA finding was 
concordant in 36 of 37 cases with tumor-sequencing data. This method 
could detect as little as 62.5 copies of mutant L858R; 125 copies of 
E709K + G719A or 625 copies of del 746–750 in the presence of 
100,000 copies of wild-type EGFR. In 21 patients on longitudinal 
follow-up for up to 18 months, SM was found in all initial plasma 
samples, except for three samples collected after recent chemotherapy. 
Nine of 16 patients (56%) who responded to TKI had undetectable 
plasma EGFR mutant. SM was present concurrently with drug-resis-
tant mutant in 44% of patients with disease progression while on TKI, 
the remaining 56% might have other mechanisms of resistance.
Conclusion: The EGFR array provides a sensitive, inexpensive, and 
robust method for monitoring non–small-cell lung cancer patients’ 
response to TKI, and obviates the need of repeated lung biopsy.
Key Words: Non–small-cell lung cancer, Plasma EGFR mutations, 
Tyrosine kinase inhibitor therapy, Follow-up, EGFR array.
(J Thorac Oncol. 2012;7: 1131–1140)
Carcinoma of the lung is the leading cause of cancer death worldwide. There are two main types, of which 
non–small-cell lung cancer (NSCLC) constitutes 80% of cases. 
Patients with NSCLC usually present with advanced, metastatic 
disease. If left untreated, they have a median survival of less 
than 5 months. Even with chemotherapy, which is often associ-
ated with significant toxicity, survival is usually prolonged by 
less than 6 months.1 The introduction of targeted therapy such 
as tyrosine kinase inhibitors (TKIs) has improved survival in 
a subset of NSCLC patients.2,3 It is now known that patients 
who respond to TKI harbor activating mutations, notably in the 
kinase domain (Exons 18–21) of the epidermal growth factor 
receptor (EGFR) gene.4–6 It is therefore advisable to sequence 
EGFR gene in tumor specimens as a prediction of response to 
TKI therapy. It has also been observed that despite initial good 
response, over time (median, 6–12 months), patients develop 
resistance to EGFR-TKIs because of the acquisition of second-
ary EGFR mutation.7,8 Clinically it would be important to mon-
itor changes in molecular profiling of biological targets and 
be able to predict relapse early, so as to make a timely switch 
to second-generation or irreversible TKIs or combination TKI/ 
chemotherapy.9,10 However, tumor samples are not always avail-
able, particularly during the course of TKI therapy when tumor 
shrinkage in response to therapy would make biopsy difficult.
Many groups have advocated the measurement of cir-
culating tumor DNA in plasma or serum samples, both at 
diagnosis and during follow-up. Detection methods ranging 
from polymerase chain reaction (PCR) plus direct sequenc-
ing to mass spectrometry genotyping11–17 have been employed, 
but their sensitivity and specificity are variable. For example, 
although the scorpion-amplification refractory mutation sys-
tem has a higher detection rate for deletional defects,13 it can 
only detect 3.7% to 4.8% of the L858R mutation in plasma 
samples.12,13 Given that exon 19 deletions and the exon 21 
L858R mutation account for approximately 85% of clini-
cally important EGFR mutations, the need to detect point 
mutations present in minute quantities in plasma or serum 
against a background of wild-type (wt) sequences is impera-
tive. Theoretically digital PCR16 in which single molecules of 
mutants (mts) can be amplified, seems the most promising. 
However, it requires both expensive hardware and consum-
ables. Previously, using cyanine 5-deoxycytidine triphosphate 
in an allele-specific arrayed primer extension (AS-APEX) 
reaction, it was possible to detect the presence of paternal 
mutation and paternal single-nucleotide polymorphisms in 
maternal plasma down to one genome equivalent.18 Others 
have shown that the use of peptide nucleic acid-locked nucleic 
University Department of Medicine, Queen Mary Hospital, Pokfulam Road, 
Hong Kong.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Vivian Chan, PhD, University Department of 
Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong. E-mail: 
vnychana@hku.hk
Supplemental digital content is available for this article. Direct  URL citations 
appear in the printed text and are provided in the HTML and PDF versions 
of this article on the journal’s web site (www.jto.org).
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/12/0707-1131
EGFR Array: Uses in the Detection of Plasma EGFR 
Mutations in Non–Small Cell Lung Cancer Patients
Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin Chan, PhD, James Chung-Man Ho, MD, 
Mary Ip, MD, Wah-Kit Lam, MD, Tai-Kwong Chan, MD, and Vivian Chan, PhD
1132 Copyright © 2012 by the International Association for the Study of Lung Cancer
Yam et al. Journal of Thoracic Oncology  •  Volume  7, Number 7, July 2012
acid (PNA-LNA) PCR clamp could enhance the sensitivity of 
detection by at least 100-fold.19 In this study, a PNA clamp 
was used in the PCR of the template, and an array based on 
AS-APEX20,21 was used to detect mutations of the EGFR gene 
in plasma samples from NSCLC patients at diagnosis and dur-
ing subsequent follow-up.
PATIENTS AND METHODS
Fifty-one patients with confirmed diagnosis of NSCLC, 
attending the Respiratory Oncology Clinic at the Department 
of Medicine, Queen Mary Hospital or the 813 Medical Centre, 
Hong Kong were recruited. Ten patients without any malig-
nancy, but age and sex matched to the NSCLC group, were 
recruited as a negative control. All patients gave informed 
consent, and the study was conducted with approval of the 
Institutional Review Board.
TKI was started for patients whose lung tumor showed 
a sensitive EGFR mutation, or for those without the benefit of 
tumor sequencing on clinical criteria alone, i.e., nonsmoker 
or ex-smoker with adenocarcinoma (only one had squamous-
cell carcinoma [no. 15 Table 2], who was started on TKI after 
chemotherapy). Some NSCLC patients received partial or full 
sponsorship for TKI therapy from pharmaceutical companies 
(as TKI therapy is not subsidized by the government health 
care system in Hong Kong). The availability of such commer-
cial sponsorship was not considered a criterion for recruitment 
into this project.
Citrated blood of 4.5 ml was collected from each sub-
ject, and these samples were centrifuged twice at 1800 g 
to separate the plasma and buffy coat. Plasma was stored 
in 1-ml aliquots and frozen until DNA extraction using the 
Qiagen DNA mini-kit (Qiagen, Hilden, Germany) accord-
ing to the Blood and Body Fluid protocol. A single blood 
sample was obtained from 30 patients as a cross-sectional 
arm. In addition, 21 patients participated in the longitudinal 
study. Fifteen were treatment naive with TKI as first-line 
therapy, the remaining six had received chemotherapy or 
radiotherapy and changed to TKI upon disease progression. 
In all cases, blood was collected before the initiation of 
TKI therapy, and on two to 11 occasions during therapy at 
their follow-up clinic. The clinical data of the entire patient 
cohort showed a male:female ratio of 24:27; age range, 38 
to 94 years (median 62 years); nonsmoker: ex-smoker or 
current smoker = 36:15; clinical staging = IB:IIA:IIIA:IIIB 
or IV = 1:1:3:46; histology of adenocarcinoma: non–small-
cell or squamous = 46:4 (one with no histology because 
tumor biopsy was not performed in view of her advanced 
age, but staging of her disease was made based on computer-
tomography findings).
These patients were observed for tumor responses and 
survival outcomes. Only 32 of the 51 patients were confirmed 
as sensitive to TKI through direct sequencing of their biop-
sied tumor specimen for presence of EGFR drug-sensitive 
mutation (SM) or absence of KRAS gene mutation. Of the 
remaining patients, five had no EGFR gene mutation in their 
tumor-DNA, and for the other 14 cases, TKI therapy was initi-
ated without the benefit of EGFR or KRAS gene sequencing 
of their tumor.
Preparation of EGFR Array
Glass slides (75 × 25 mm dimension) were treated as 
described previously22 and left for at least 1 month before 
spotting. Oligonucleotide primers (5 μM) pertaining to both 
the wt and mt sequences in Exons 18–21 of the EGFR gene 
were designed and spotted on the precoated glass slides by 
contact printing with a chipmaker pin (Cartesian, Irvine, CA) 
on the arrayer (Prosys Gantry 5510, Cartesian). The slides 
were left in a humid chamber for 3 hours, then allowed to dry, 
and stored at room temperature ready for use. Each slide con-
tains four sections of oligonucleotides for the analysis of four 
different test samples. In addition, in each section, each oligo-
nucleotide was spotted six times. Table 1 shows the mutations 
in Exons 18–21 of the EGFR gene that were spotted on the 
array. For convenience, separate arrays were prepared for the 
detection of exons 18–21 missense and insertional mutations, 
exons 20–21 mutations, and exon 19 deletional mutations, 
respectively, each containing in addition primers for the detec-
tion of common drug-resistance mutations (RM) on the right.
Preparation of Template and Array Extension
Template for primer extension was prepared by PCR. 
Exons 18–21 of the EGFR gene were amplified individu-
ally using one-tenth volume of DNA extracted from 1 ml 
of patient’s plasma, in a 25-μl reaction volume containing 
1× Accuprime buffer (containing deoxyribonucleotide tri-
phosphate), 400-nM MgCl
2
, 200-nM primers, and 0.5 U 
Accuprime (Life Technologies Corp, Carlsbad, CA). After an 
initial hot start of 95°C for 5 minutes, 20 cycles’ amplifica-
tion of 95°C for 10 seconds, 74°C for 15 seconds, and 62°C 
for 20 seconds were followed by another 10 cycles’ amplifi-
cation with an additional 2 seconds’ extension time added to 
each cycle.
Five μl of the first PCR product was used for a second 
seminested PCR under the same conditions, but with the addi-
tion of either 15-pM (exon 18), 100-pM (exon 19), or 50-pM 
(exon 20 and exon 21) PNA-clamp in the reaction mix of 50 
μl and 1 U Accuprime (Life Technologies). An additional 10 
cycles’ amplification was made with a final extension time of 
62°C for 7 minutes.
Three μl of denatured salmon sperm DNA (0.6 μg/ml) 
was added to the entire amount of the second PCR product, 
which was precipitated with ammonium acetate and isopropa-
nol, and resuspended in 50 μl of H
2
0. Five μl of this second 
PCR product was then used for asymmetric PCR (A-PCR) 
with a 1:20 ratio of forward:reverse primer, in 100-μl reaction 
volume and 5U Faststart Taq polymerase (Roche, Mannheim, 
Germany), yielding essentially A-PCR product. The A-PCR 
conditions consisted of a hotstart of 95°C for 5 minutes, then 
20 cycles of 95°C for 10 seconds, 58°C for 20 seconds, 72°C 
for 10 seconds followed by another 40 cycles of the same, 
with 2 seconds’ increase in extension time per cycle and a 
final extension of 72°C for 7 minutes. (Primers sequence and 
PNAs sequence are available on request.)
The A-PCR product was precipitated with ammonium 
acetate and isopropanol as described earlier, resuspended in 
25 μl of H
2
O and column-purified (Auto-Seq G50, Amersham 
Pharmacia Biotech, Little Chalfont, United Kingdom) to 
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remove unincorporated deoxyribonucleotide triphosphates. 
The purified A-PCR product was then dried and resuspended 
in 2.5 μl of H
2
O for analysis.
Allele-Specific Arrayed Primer Extension
To reduce nonspecific binding, the arrayed slide was 
preincubated in 15 μl of 1xTaq buffer (Applied Biosystems 
Inc., Foster City, CA) under a LifterSlip (Erie Scientific, 
Portsmouth, NH) in the hybridization cassette (Telechem, 
Sunnyvale, CA). The entire assembly was submerged in a 
63°C water bath for 30 minutes. The slides were rinsed with 
water, spun dry at 110 g for 5 minutes, then overlay with 
the AS-APEX reaction mix containing A-PCR product and 
reagents as described previously.21 For each plasma-DNA 
sample, A-PCR product pertaining to either Exon 18, 19, 
or 21 was analyzed together with the A-PCR product from 
Exon 20 (which harbors the TKI-resistant mutations), with 
the AS-APEX reaction proceeding at 63°C for 30 minutes. 
Upon termination of the reaction, the slide was washed, spun 
dry, and scanned at an emission wavelength of 670 nm and 
10-μm resolution (ScanArray 5000; GSI Lumonics, Boston, 
MA), with the laser power set at 60 and gain at 65. The Scan-
Array software was used to capture the fluorescent signal but 
no further manipulation was needed.
Sensitivity of the Array
Lung tumor DNA carrying either Exon 18 E709K and 
G719A, Exon 19 deletion 746-50 or Exon 21 L858R muta-
tions were cloned into pCR2.1-TOPO vector using reagents 
from the TOPO cloning kit (Invitrogen, Carlsbad, CA). 
Plasmid DNA of each clone was prepared and used to assess 
the sensitivity of this array method.
One hundred thousand copies of each mt-cloned DNA 
together with 100,000 copies of wt EGFR from total genomic 
DNA of a healthy individual (300 ng, based on 6 pg genomic 
DNA equals one genome equivalent, with two copies of wt 
EGFR) were used as a single sample to generate A-PCR tem-
plate and analyzed on the array. Subsequent samples con-
taining 10,000, 5000, 2500, 1250, 625, 312.5, 125, 62.5, and 
31.25 copies mt in the presence of 100,000 copies of wt were 
also analyzed. The entire experiment was repeated with the 
different concentrations of mt in the presence of 10,000 copies 
of wt (30 ng genomic DNA) only.
RESULTS
Sensitivity of the Array
Using PNA in the second PCR as described earlier, it was 
possible to detect the presence of 125 copies of Exon 18 and 62.5 
copies of Exon 21 mts or 625 copies of Exon 19 deletional mt, 
respectively in the presence of 100,000 copies of the wt EGFR 
from 300-ng total genomic DNA (Fig. 1A). A lower detection 
limit was achievable if less genomic DNA (30 ng) was used as 
background, viz., 31 copies of Exon 18 mt, 10 copies of Exon 
21 mt, and 125 copies of Exon 19 deletional mt (Fig. 1B). 
Supplemental figures are available at http://links.lww.com/
JTO/A276.
TABLE 1. List of EGFR Mutations Detectable on the EGFR Array
Drug-Sensitive Mutations
Drug-Resistant 
Mutations 
Missense & 
Termination Mutations
Deletions and 
Insertions
Exon 18 L692P
E709A
E709G
E709K
G719A
G719C
G724S
Exon 19 W731X del745-9 D761Y
W731X del746-50
E734K del746-51
LR747-8FP del746-52
A750P del747-49
del747-50
del747-51
del747-52
del747-53
del752-9
del746-50DP
del746-50IP
del746-51A
del746-51VP
del746-52D
del746-52V
del746-53VS
del747-50P
del747-51P
del747-51Q
del741-53Q
del741-53S
Exon 20 V765M ins761EAFQ S768I
S768C ins769AS V769L
V769M ins769GS insN771GT
H773R ins769GV ins770NPG
V774M ins770SVD ins770SVQ
R776H insN771GF T 790M
G779F ins772PR1
G779S ins772PR2
Q787R ins773NPH
L798H ins773VH
K806E
L814P
Exon 21 L833V
V834L
H835L
L838V
A839T
K846R
L858M
L858R
L861Q
L861R
Note that oligonucleotide primers for the drug-resistant mutants are located at one 
end of the array.
EGFR, epidermal growth factor receptor.
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FIGURE 1. A, Sensitivity experiment showing the detection of A-PCR products of exon 21 of the EGFR gene prepared from (A) 
equal amounts (100,000 copies) of cloned L858R mutant (mt) and wild-type (wt, from 300 ng normal genomic DNA), (B) 5000 
copies L858R mt in the presence of wt, (C) 62.5 copies L858R mt in the presence of wt, and (D) 31 copies L858R mt in the 
presence of wt. Each panel shows a section of the array where oligonucleotide primers for detecting mutations in Exon 20 and 
Exon 21 of the EGFR gene are spotted. Primers are spotted twice, in triplicate rows. Wt = primers for wild type sequence and 
mt = primer for mutant sequence. The codon position of these sequences along the gene is indicated at the top of each panel. 
Note that fluorescent signal intensity is white > red > yellow > green, with blue as background. B, Sensitivity experiment show-
ing the detection of A-PCR products of exon 18 of the EGFR gene prepared from (A) equal amounts (10,000) copies of cloned 
E709K + G719A mt and wt (from 30 ng normal genomic DNA), (B) 31 copies of the same Exon 18 mt and 10,000 copies wt, 
(C) equal amounts (10,000 copies) of cloned Exon 19 del 746-50 mt and wt (30 ng genomic DNA), and (D) 125 copies Exon 
19 mt in the presence of 10,000 copies wt. A-PCR, asymmetric PCR; EGFR, epidermal growth factor receptor; mt, mutant; wt, 
wild type.
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TABLE 2.  Clinical Data, Tumor and Plasma Mutation Results of All Patients
No Code Sex/Age Smoking Status Staging Histology Tumor/Biopsy Mutation Results
Previous Treatment & 
Clinical Statusa
Plasma Mutation 
Results
 1 L002 F/62 NS (PS) IIIA AD Exon 21 L858R Chemo-PR L858R
 2 L006 F/84 EX IV AD Exon 21 L833V and L858R Pre-treatment L833V, L858R
 3 L008 F/60 NS IV AD Exon 21 L858R Pre-treatment L858R
 4 L009 M/56 NS IV AD Exon 21 L858R Chemo-SD L858R
 5 L010 F/72 NS IV AD Exon 21 L858R Pretreatment L858R
 6 L011 F/60 NS IIIB AD Exon 21 L858R Pretreatment L858R
 7 L013 F/60 NS (PS) IIIB AD Exon 21 L858R Pretreatment L858R
 8 L014 M/79 SM IV AD Del exon 19 (15bp) Pretreatment Del 746–50
 9 L016 F/77 NS (PS) IV AD Del exon 19 (15 bp) Pretreatment Del 747–51
10 L017 F/51 NS (PS) IV AD Del exon 19 Pretreatment Del 747–51
11 L018 M/80 EX (PS) IIIA AD Exon 21 L861Q Pretreatment L861Q, L861R
12 L019 M/48 NS IV AD Exon 21 L858R Pretreatment L858R
13 L001 M/48 SM IIIB AD Wt Chemo - RT-PR L858R
14 L004 M/76 EX IV AD ND Pretreatment Del 746–50
15 L007 M/65 EX IIIB SCC ND Chemo-SD L858R
16 L012 F/86 NS IV AD ND Pretreatment Del 745–51
17 TKL001 M/55 NS IV AD Exon 21 L858R Pretreatment L858R
18 TKL002 F/69 NS IV AD Del exon 19 RT Del 747–51
19 TKL003 M/62 NS (PS) IIIB AD Del exon 19 (15bp) Chemo-PR Del 746–50
20 TKL005 M/66 NS (PS) IV AD Exon 21 L858R Pretreatment L858R
21 TKL006 F/71 NS IIIB AD Exon 21 L858R Pretreatment L858R
22 TKC001 F/51 NS IV AD Exon 21 L858R Pretreatment L858R
23 TKC002 F/61 NS IV AD Del exon 19 Pretreatment Del 747–50
24 TKC003 F/93 NS IV AD Exon 18 mutation TKI-PR E709K, G719A
25 TKC004 F/62 NS IV AD Del Exon 19 746 - 50 TKI-PD Del 747–50
26 TKC005 F/76 NS IV AD Exon 21 L858R TKI-Chemo-PD L858R
27 TKC006 M/87 EX IV AD Exon 18 G719A Pretreatment G719A
28 C003 F/48 NS IV SCLC+AD Del exon 19 Pretreatment Del 747–51
29 C004 M/57 NS IV AD Exon 21 L858R Pretreatment L858R
30 C007 F/74 NS IV AD Del exon 19 (18bp) Pretreatment Del 747–51
31 C008 F/52 NS IV AD Exon 21 L858R Pretreatment L858R
32 C014 M/63 SM IV AD Exon 21 L858R Pretreatment L858R
33 C015 M/62 NS IIIA AD Exon 21 L858R Pretreatment L858R
34 C016 M/57 NS IV AD Del exon 19 Pretreatment Del 747–51
35 C017 F/39 NS IV AD Del exon 19 Pretreatment Del 747–51
36 C018 M/38 NS IV AD Del exon 19 Pretreatment Del 747–50
37 C013 F/83 NS IV AD Wt Pretreatment Wt
38 C021 M/48 NS IV AD Wt Chemo-PD Wt
39 C022 M/48 NS IV AD Wt Pretreatment Wt
40 C023 M/46 EX IV AD Wt Pretreatment Wt
41 C001 F/81 SM IB AD ND Pretreatment Del 747–51
42 C002 M/58 EX IV AD ND Chemo-RT Del 747–51
43 C005 M/77 EX IV NSCLC ND Pretreatment L858R
44 C006 F/60 SM IV NSCLC ND TKI-PD Del 747–51
45 C009 M/55 NS IV AD ND TKI-GPR Del 747–51
46 C010 M/62 NS IV AD ND Pretreatment L858R
47 C011 F/61 NS IIIB AD ND Pretreatment L858R
48 C012 F/75 NS IV AD ND Pretreatment Del 747–50, 747–52
49 C019 M/77 EX IV NSCLC ND Pretreatment L858R
50 C020 F/63 NS IIA AD ND Surgery Wt
51 TKC007 F/94 EX IIIB ND ND Pretreatment L858R
NS, nonsmoker; PS, passive smoker; EX, ex-smoker; SM, current smoker; AD, adenocarcinoma; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; SCC, 
squamous cell carcinoma; wt, wild type; ND, not done.
aThis relates to the patients’ condition at the time of the first blood collection.
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All Patients Studied
A total of 51 patients were studied, 30 in the cross-sec-
tional group and 21 in the longitudinal study. Table 2 lists the 
clinical data and the results of lung tumor and plasma EGFR 
mutations in the entire cohort.
Lung tumor specimen from 37 patients had been 
sequenced, 32 were positive for EGFR drug-SM, and five with 
wt only. The mutation status for tumor and plasma-DNA were 
concordant in 36 cases. One patient (no. L001), whose tumor 
was thought to have wt EGFR, was found to carry the L858R 
in his plasma-DNA. This patient also participated in the lon-
gitudinal follow-up study.
It was also possible to identify the presence of SM in 
the plasma-DNA of all but one of the 14 patients whose lung 
tumor had not been sequenced (Table 2, patient no. 50). The 
plasma-DNA SM identified in 46 of 51 patients include 23 
with exon 21 L858R, 19 with deletions of exon 19 (six were 
deletions of codon 747–50; 12 were deletions of codon 747–51, 
and one with both deletions of codon 747–50 and codon 747–52), 
one patient with exon 18 G719A and three other patients with 
double mutations (one with exon 18 E709K and G719A, one 
with exon 21 L833V and L858R and a third case with both 
exon 21 L861Q and L861R).
To test the specificity of the arrayed oligonucleotides, 
10 age- and sex-matched control patients (without malig-
nancy) served as negative control. All were found to have only 
wt EGFR in their plasma-DNA (Table 3).
Longitudinal Follow-up Study
Eighty-eight serial blood samples, collected from 21 
patients during longitudinal follow-up were analyzed (see 
Appendix, Supplemental Digital Content 1, http://links.lww.
com/JTO/A275). All patients were confirmed to have SM 
EGFR mutations either in their tumor or in plasma, before the 
initiation of TKI (gefitinib or erlotinib) therapy.
Table 4 was derived from the longitudinal crude data (see 
Appendix, Supplemental Digital Content 1, http://links.lww.
com/JTO/A275) of detectable plasma EGFR mts, the duration 
of treatment (grouped at 3-monthly intervals) and the clinical 
response of the disease at that time interval (classified as good 
partial response [GPR] with less than 10% residual disease; 
partial response [PR] with less than 50% residual disease; stable 
disease [SD] with 50% to 90% residual disease, and progressive 
disease [PD]). The absence of mutation (ND) or the presence of 
SM or emergence of RM (T790M only in this study) was com-
puted for each time interval and for each disease status.
In the initial 21 plasma samples, SM was detected in 18. 
The three patients (L001, L002, and TKL003) with baseline neg-
ative result were found to have positive SM in their subsequent 
follow-up plasma samples. They had all received four courses of 
chemotherapy with or without radiotherapy and were in GPR/
PR at the initial blood sampling. At 4 to 6 months after TKI 
treatment, 16 of 19 patients (84%) had GPR/PR or SD and nine 
(56%) had undetectable EGFR mutation in their plasma. Among 
the three patients with PD, two had in their plasma-DNA, a drug 
RM, T790M together with the initial SM (*, Table 4).
During the 18 months’ follow-up, nine patients developed 
PD and four (44%) had T790M detectable in plasma, eight had 
persistence of the initial SM whereas one was negative for EGFR 
TABLE 3.  Plasma-DNA EGFR Analysis in Age-/Sex-Matched 
Patients Without Malignancy
No. Code
Sex/
Age Diagnosis
Plasma Mutation 
Results
 1 MC 001 (12167) F/35 Polymyositis, 
interstitial lung 
disease
Wt
 2 MC 002 (12156) F/46 Iron-deficiency anemia Wt
 3 MC 003 (12149) F/53 Polycythemia Wt
 4 MC 004 (12169) F/57 Hypertension Wt
 5 MC 005 (12151) F/81 Chronic obstructive 
pulmonary disease
Wt
 6 MC 006 (12168) M/41 Pneumonia with 
empyema
Wt
 7 MC 007 (12162) M/53 Hypertension Wt
 8 MC 008 (12159) M/58 Protein S deficiency, 
diabetes mellitus
Wt
 9 MC 009 (12161) M/60 Old tuberculosis 
diabetes mellitus
Wt
10 MC 010 (12163) M/74 Gout, hypertension Wt
Wt, wild type; M, male; F, female.
TABLE 4.  Longitudinal Data in 21 Lung Cancer Patients
Duration 
(month)
Initial
Number of Plasma Samples With EGFR Mutations According to Disease Status
GPR/PR SD PD Total
n ND SM RM n ND SM RM n ND SM RM n ND SM RM n ND SM RM
0–3 21 3 18 0
4–6 8 6 2 0 8 3 5 1a 3 0 3 2a 19 9 10 3a
7–9 7 3 3 2a,b 3 2 1 0 3 1 2 0 13 6 6 2a,b
10–12 4 0 4 0 1 0 0 1b 1 0 1 1a 6 0 5 2a,b
13–18 1 0 1 0 2 0 1 1b 2 0 2 1a 5 0 3 2a,b
n (%) 20 9 (45) 10 (50) 2 (10) 14 5 (35) 7 (50) 3 (21) 9 1 (11) 8 (88) 4 (44) 43 15 24 9
GPR/PR, good partial remission/partial remission; SD, stable disease; PD, progressive disease; n, number of plasma samples; ND, not detected; SM, sensitive mutation; RM, 
resistant mutation (T790M); EGFR, epidermal growth factor receptor.
Coexistence of SM and RM.
RM only, e.g., 3a,b = all 3 samples with coexistence of SM and RM, 2a =1 sample with coexistence of SM & RM and 1 sample with RM only.
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mutation (Table 4). In total, nine plasma samples obtained  during 
various times of follow-up showed T790M, six occurred in asso-
ciation with the initial SM but three occurred alone (Table 4). 
Using Kaplan-Meier analysis, the median progression-free sur-
vival in the 16 responsive patients was 14 ± 2.7 months.
One patient (L002) had received two courses of chemo-
therapy before TKI; blood collections were made just before 
TKI and during attendance at follow-up clinic in the subse-
quent 2 years. The clinical course and results of EGFR screen-
ing were detailed in Table 5. After chemotherapy, no SM was 
detected. After 3 months, L858R mt was seen. Blood taken at 
7 months showed the emergence of a weak signal for T790M. 
Clinically, the tumor was downstaged from IIIA to Ib and the 
patient underwent surgery for removal of her residual tumor at 8 
months. However, resected mediastinal lymph node showed per-
sistence of disease. In the blood sample taken a fortnight later, 
the L858R mt had disappeared and only T790M remained. Post 
surgery, the patient was taken off TKI but received daily radio-
therapy for a fortnight. No circulating EGFR mutations were 
detected during radiotherapy except for T790M. Her TKI was 
resumed and her plasma samples since then only showed posi-
tive signal for L858R. At 21 months (13 months after resection 
and adjuvant radiotherapy), she was still in clinical remission.
A second case (TKL001) (Table 5) diagnosed as 
Stage-IV adenocarcinoma of the lung presented with relapse, 
with bilateral lung masses and right cervical lymph node in 
February 2009 (time of recruitment into study). On initial 
diagnosis in March 2007 (22 months ago), he had been treated 
with Gefitinib for 18 months. Plasma taken before treatment 
showed L858R mutation only. Initial PR was achieved and 
upon relapse, he received two courses of chemotherapy in 
October 2008 and January 2009, respectively. Plasma sam-
ples taken between February to July 2009 (at 19–24 months) 
still showed presence of L858R only (Fig. 2A), although he 
had relapsed with metastasis to the brain. Radiotherapy to the 
brain and another course of chemotherapy (Pemetrexed and 
Temozolomide for 3 months) failed to control disease. When 
his lungs worsened, he was started on Erlotinib in September 
2009 (at 25 months); plasma samples showed presence of 
T790M only at 28 to 30 months (Fig. 2B). The patient showed 
initial improvement with this second TKI and good PR for 
4 months. As disease progressed, there were intense signals 
for both L858R and T790M at 34–37 months (Fig. 2C). He 
was given further chemotherapy and Erlotinib and Sunitinib. 
He eventually succumbed to allergic alveolitis from Sunitinib, 
with persistent intense signals for L858R only (Fig. 2D). The 
drug-resistant T790M clone of tumor cells had disappeared.
DISCUSSION
Since the initial description of the AS-APEX technol-
ogy,20 this technique has been successfully applied to the devel-
opment of a number of diagnostic arrays by our group and others 
for mutation detection in α and β thalassemias,18,21,23 hemo-
philia B,24 and hepatitis B.25 The sensitivity of the technique for 
plasma-DNA had previously been determined as down to one 
genome equivalent.18 In this study, to detect EGFR mutations 
in circulating tumor cells, a seminested second PCR was used 
to ensure specific amplifications of the EGFR exon fragments. 
In addition, to suppress amplification of the genomic wt EGFR 
present, a PNA clamp was used. For a PNA clamp to func-
tion effectively, it should be an approximately 13 to 20 base 
oligonucleotide matching the wt sequence, where the expected 
mutation would lie in the middle of sequence.19 This meant that 
unless mutations are within one to four bases of each other, dif-
ferent PNA clamps would be required for individual mutation. 
For example, although it is possible to design a single PNA 
clamp for the exon 19 deletions, two different clamps would 
be needed for the detection of L858R and L861Q despite both 
being in exon 21. Thus, prior sequencing of the tumor speci-
men to identify the EGFR mutation would be useful. This may 
not be possible for every patient because the tumor could be 
deep-seated and difficult to approach with conventional biopsy 
techniques. However, given that just two molecular defects, 
viz., the L858R and exon 19 deletions account for 75% of the 
EGFR SMs found in Asian patients with NSCLC,26 we were 
able to identify the mutations in all but one of the 51 patients 
in this study, despite absence of tumor-sequencing result in 
14 of them (Table 2). Because no sequencing had been per-
formed on her tumor sample, this remaining patient (C020, 
Table 2) with no detectable mutation in her plasma-DNA, 
may well be carrier of only the wt EGFR gene. The sensi-
tivity experiment showed that this array is able to detect the 
presence of as little as 125 copies of mt Exon 18 E709K + 
G719A or 62.5 copies of Exon 21 L858R and 625 copies of 
mt Exon 19 del 746–50 each in the presence of 100,000 cop-
ies of wt EGFR. This method is thus more sensitive compared 
with many other plasma- or serum-DNA detection techniques 
described to date.11–15,17 The increased sensitivity is a result of 
the synergistic effects of the PNA clamp, the incorporation of 
cyanine 5-deoxycytidine triphosphate in the AS-APEX reac-
tion with laser scanning of the signal in the extended strands 
and the increased number of amplification cycles. For the lat-
ter, a high-fidelity polymerase, Accuprime, was used to mini-
mize PCR error. The improved sensitivity of PNA/LNA-PCR 
had been demonstrated recently in re-biopsy samples of lung 
cancer patients,27 enabling the detection of T790M in more 
patients than by conventional methods. One observation from 
this study is the need to titrate the amount of PNA required, as 
too small an amount will not be sufficient to suppress the vast 
quantity of wt EGFR normally present in genomic DNA of the 
patient, whereas too much may also cause suppression of the 
mt derived from the circulating tumor DNA.
In the longitudinal study, after several months on TKI, 
patients with GPR/PR were observed to have lost their SM tran-
siently (56% at 4–6 months and third sample for patient L002, 
and fifth sample for patient TKL001, Fig. 2B). This could be 
ascribed to the efficacy of therapy or it could be that the amount 
of mt in plasma was below the detection limit of this array 
method (determined as 62.5 copies L858R mt/100 μl plasma). 
In this study, 84% of patients with EGFR SM responded to TKI 
treatment and the median progression-free survival was 14 ± 
2.7 months, comparable with previous reports.7,8,28
The appearance of the RM T790M predicted for disease 
progression. Although previous reports indicated that the L858R 
and T790M mutations are often seen in cis (L858R should always 
be present despite the development of the secondary RM), 
they can also occur in trans or in different population of tumor 
cells,29,30 as observed in a number of our patients (three of nine 
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samples in Table 4 and both L002 and TKL001). Recent  evidence 
showed that the subset of EGFR-mt lung cancer patients har-
boring T790M mutation after progression on TKI have signifi-
cantly longer postprogression survival than those with acquired 
resistance but lacking T790M.31 The latter group was associ-
ated with an earlier development of new metastatic sites and a 
poor performance status, contributing to their shorter survival. 
Arcila et al.27 advocated the detection of T790M mutation as an 
“acquired” prognostic biomarker. Their use of LNA to augment 
sequencing of the tumor had enabled the detection of T790M 
when present in as little as 0.1% of DNA. In the present array 
method, an even higher sensitivity was achieved. The detection 
limit is variable for different EGFR mutations, ranging from 625 
copies of Exon 19 deletion 746–50 to 62.5 copies of L858R in 
the presence of 100,000 copies of wt. For patient TKL001, with 
further progression of disease, the use of chemotherapy in com-
bination with erlotinib resulted in the reappearance of L858R 
and elimination of T790M in later plasma samples (Fig. 2D). 
The presence of a different clone of tumor cells from the original 
one could explain this finding. Alternatively, this could be an 
indication for persistence in TKI treatment or combination TKI-
chemotherapy despite the development of TKI RM. Oxnard et 
al.31 suggested that the beneficial effect of maintaining chronic 
EGFR-TKI therapy after developing resistance would help pre-
vent the growth of TKI-sensitive clones, and additional cyto-
toxic therapies would be needed to treat the subset of resistant 
clones.32 Recently, through systematic genetic and histological 
analyses of repeated lung biopsies in 37 patients with drug-resis-
tant NSCLC carrying EGFR mutations, Sequist et al.33 found 
that T790M could be lost in the absence of continued selective 
pressure of TKI treatment, and such cancers could then become 
sensitive to a second round of TKI. Similar finding was noted in 
both cases L002 and TKL001 described in this study (Table 5 
and Fig. 2D). In the current study, nine patients developed pro-
gressive disease and T790M mutation was found in four (44%). 
This is similar to that reported by Sequist et al.33 using second 
lung biopsy, where T790M occurred in 49% of cases, whereas in 
the remaining cases, the mechanisms of resistance were EGFR 
and MET gene amplification, mutations of the PIK3CA gene (a 
subunit of the phosphatidylinositol-3-kinase), and transforma-
tion from NSCLC to small-cell lung cancer.
The array technique has proven to be a robust method, suit-
able for use in any routine clinical biochemistry or DNA diagnos-
tic laboratory. Once spotted, the oligonucletoide primers are very 
stable and the array can be stored at room temperature for up to 6 
months.21 The arrays can be spotted at one center and shipped to 
other laboratories for use. This avoids the need to purchase hard-
ware such as the arrayer, and all that would be required are a water 
bath, bench-top centrifuge, PCR cycler, and a small laser scanner 
at 670 nm. The outlay would be significantly less than techniques 
such as digital PCR or mass spectrometry genotyping. With laser 
scanning, the laser power was set at 60 and gain at 65, using the 
Scanarray software (GSI Lumonics) supplied with the machine, 
no further manipulation of the data is needed. This sensitive tech-
nique should allow the clinicians to follow up patients’ disease 
progress in plasma, complementing other monitoring param-
eters, and also allows them to make timely decision in treatment 
regime, obviating the need of repeated tumor biopsies.TA
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